CAMLINFINE: Revenue grew, but margin pressure and liquidity challenges drove a steep Q2 earnings decline

What happened

Camlin Fine Sciences reported that Q2 FY27 revenue rose 9.15% year over year, but adjusted EBITDA fell sharply and profit from continuing operations turned into a loss. Higher raw-material costs, limited ability to pass them on, and cash strains hurt margins. A rights issue of up to Rs 2,500 mn was approved.

Confirmed

Global impact / market context

Revenue growth without profit shows the company sold more but kept less from each sale, as input costs rose faster than it could raise prices. The planned rights issue, which means selling new shares to existing investors, would bring in cash to ease funding strain and support operations.

Analyst inference

This points to pressure across chemical makers that cannot quickly pass raw-material inflation to customers. Investors may weigh whether the cash raise fixes the balance sheet or merely buys time, and whether weak profit per sale persists once input costs settle.

Analyst inference

What to watch

1. Watch whether the approved rights issue of up to Rs 2,500 mn is completed and how much cash it actually raises for the company. Confirmed
2. Track management plans to recover profit per sale, such as price increases or cost cuts, since raw-material inflation and limited pass-through pressured margins. Proposed
3. Monitor whether cash available improves enough to fund daily operations and capital spending without new borrowing, given the reported liquidity pressures, which means strains on ready cash. Analyst inference

Evidence

• Original source link unavailable